​

Larimar Therapeutics Stock (NASDAQ:LRMR)

ForecastOwnershipFinancialsChart
Larimar Therapeutics by TradingView

Previous Close

$3.98

52W Range

$3.01 - $13.68

50D Avg

$6.97

200D Avg

$7.64

Market Cap

$255.86M

Avg Vol (3M)

$859.94K

Beta

0.71

Div Yield

-

LRMR Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

42

IPO Date

Jun 19, 2014

Website

LRMR Performance

LRMR Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-41.76M$-36.53M$-50.47M
Net Income$-36.95M$-34.18M$-50.31M
EBITDA$-41.45M$-36.53M$-50.47M
Basic EPS$-0.84$-1.33$-2.93
Diluted EPS$-0.84$-1.33$-2.93

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CNTACentessa Pharmaceuticals plc
MRUSMerus N.V.
DAWNDay One Biopharmaceuticals, Inc.
ALECAlector, Inc.
STROSutro Biopharma, Inc.
SPROSpero Therapeutics, Inc.
SRZNSurrozen, Inc.
CABACabaletta Bio, Inc.
BOLTBolt Biotherapeutics, Inc.
KROSKeros Therapeutics, Inc.
IKNAIkena Oncology, Inc.
SNDXSyndax Pharmaceuticals, Inc.
PCVXVaxcyte, Inc.
IMRXImmuneering Corporation
KZRKezar Life Sciences, Inc.
CHRSCoherus BioSciences, Inc.
CELCCelcuity Inc.